MedPath

JNTX-102 Advanced Drug Monograph

Published:Aug 25, 2025

Generic Name

JNTX-102

An Investigative Report on JNTX-102: Profiling and Strategic Analysis of Novel Oncology Therapeutics from January Therapeutics and GlycoNex Inc.

I. Executive Summary

This report provides a comprehensive analysis of the investigational therapeutic designation "JNTX-102." Initial investigation reveals that a singular, publicly documented drug with this exact identifier does not exist within the provided materials.[1] The query most likely pertains to one of two distinct and strategically significant oncology programs, identified through analysis of the nomenclature and the broader biopharmaceutical development landscape. This report deconstructs this ambiguity to deliver a detailed evaluation of these two programs:

JNTX-101, a preclinical asset from January Therapeutics, and GNX-102, a clinical-stage program from GlycoNex Inc.

January Therapeutics' JNTX-101 represents a novel drug delivery platform designed to enhance the therapeutic index of established chemotherapies. JNTX-101 is an albumin-bound nanoparticle formulation of a gemcitabine prodrug.[3] The program's core innovation lies in its dual-targeting strategy: leveraging the natural transport properties of serum albumin to improve pharmacokinetics and utilizing a unique biological mechanism of cellular uptake mediated by Caveolin-1 (Cav-1).[3] This positions Cav-1 as a potential predictive biomarker, enabling a precision medicine approach for solid tumors, such as pancreatic and lung cancer, where gemcitabine is a standard of care.[4] Currently in the preclinical stage of development, JNTX-101 embodies a "smarter chemotherapy" approach, aiming to improve the efficacy and safety of a proven cytotoxic agent rather than discovering a new biological pathway.

GlycoNex Inc.'s GNX-102 is a first-in-class, clinical-stage humanized monoclonal antibody (mAb) that targets novel tumor-associated carbohydrate antigens (TACAs), specifically the Lewis-Y antigen, which is highly expressed across a wide range of solid tumors.[6] The program has successfully completed a Phase 1 clinical trial (NCT04250597), which established a strong safety and tolerability profile and determined a maximum tolerated dose (MTD).[6] Following this foundational study, GlycoNex has made a pivotal strategic decision to advance the program as an

antibody-drug conjugate (GNX-102-ADC).[10] This evolution aims to harness the antibody's proven tumor-targeting specificity to deliver a highly potent cytotoxic payload, thereby significantly amplifying its therapeutic effect. This positions the GNX-102 program squarely within the high-growth, high-value ADC market.

In conclusion, while both programs address significant unmet needs in oncology with innovative platform technologies, they represent distinct investment and strategic profiles. January Therapeutics' JNTX-101 is an early-stage asset with a de-risked payload but a novel, unproven targeting mechanism that requires clinical validation. GlycoNex's GNX-102 program is clinically more advanced, having established human safety for its targeting moiety, and is now entering the highly competitive but commercially validated ADC arena. The lack of publicly available quantitative efficacy data from the GNX-102 Phase 1 trial is a key consideration, suggesting the pivot to an ADC was a necessary step to unlock the platform's full therapeutic potential. Key upcoming catalysts—namely the Investigational New Drug (IND) filings and initial clinical data for both JNTX-101 and GNX-102-ADC—will be critical inflection points in determining their future valuation and strategic importance.

II. Deconstruction and Clarification of the "JNTX-102" Designation

### Initial Findings and Rationale for Investigation

An exhaustive search for a therapeutic agent with the specific designation "JNTX-102" yields no definitive results corresponding to a singular, well-defined drug in development.[1] The identifier appears in non-specific databases or parts lists without context, but not in regulatory, clinical, or scientific literature as a distinct pharmaceutical asset.[2] This ambiguity is a critical finding, suggesting the query may stem from early-stage, incomplete, or potentially erroneous intelligence. Such situations are common in competitive analysis and necessitate an investigative approach that clarifies the landscape to provide actionable information. Therefore, this report is structured to first deconstruct the query by systematically eliminating irrelevant entities and then to build a robust, data-driven case for the most probable and strategically relevant candidates.

### Systematic Exclusion of Irrelevant "-102" Compounds

The suffix "-102" is a common nomenclature pattern in pharmaceutical development, leading to numerous unrelated compounds that could be a source of confusion. To establish a clear focus, the following agents, identified in the research, are definitively excluded from the primary analysis:

  • TAS-102 (Lonsurf): This is an FDA-approved oral anti-cancer drug combining two active agents: trifluridine, a nucleoside analog, and tipiracil, a thymidine phosphorylase inhibitor.[12] It is marketed by Taiho Pharma for the treatment of metastatic colorectal and gastric cancers.[14] It is excluded due to its established market presence, distinct chemical composition, and lack of any connection to a developer designated "JNTX".[16]
  • GTX-102 (Apazunersen): This is an investigational antisense oligonucleotide (ASO) being developed by Ultragenyx Pharmaceutical for Angelman Syndrome, a rare neurogenetic disorder.[17] It functions by inhibiting the UBE3A antisense transcript to reactivate expression of the paternal UBE3A allele in the central nervous system.[20] It is excluded based on its completely different therapeutic area (neurogenetics vs. oncology), modality (gene therapy vs. small molecule/antibody), and sponsor.[21]
  • TNX-102 SL: This is a sublingual tablet formulation of cyclobenzaprine developed by Tonix Pharmaceuticals for the management of fibromyalgia.[25] Its mechanism involves targeting non-restorative sleep.[27] It is excluded due to its non-oncology indication, distinct modality, and different developer.[28]
  • ONCOS-102: This is an investigational oncolytic adenovirus developed by Targovax.[31] It is a form of virotherapy designed to selectively infect and replicate within cancer cells, leading to immunogenic cell death and stimulating a systemic anti-tumor immune response.[32] It is being studied in mesothelioma, melanoma, and other solid tumors.[33] It is excluded because it is a biological therapeutic (virotherapy) from a different sponsor.
  • NKTR-102 (Etirinotecan Pegol): This is a long-acting topoisomerase-I inhibitor developed by Nektar Therapeutics for heavily pretreated, advanced breast cancer.[35] The BEACON Phase 3 trial did not demonstrate a significant improvement in overall survival versus treatment of physician's choice.[35] It is excluded due to its specific chemical identity and different sponsor.
  • Other "-102" Designations: Several other investigational agents with this suffix appear in clinical trial databases. These include GI-102, an immunocytokine from GI Innovation [37]; SC-102, a peptide-drug conjugate from Tianjin ConjuStar Biologics [40]; and PTX-102, an mRNA vaccine from Providence Therapeutics.[41] All are excluded as they are distinct programs from different developers with unique mechanisms of action.

The methodical exclusion of these numerous unrelated assets is a crucial analytical step. It prevents strategic miscalculations that could arise from mistaken identity—for instance, conflating the neurogenetic therapy GTX-102 with the oncology-focused GNX-102—and establishes a foundation of precision for the subsequent deep-dive analysis.

### Justification for Focusing on JNTX-101 and GNX-102

Based on the available evidence, two programs emerge as the most plausible subjects of the original query. The analysis proceeds by focusing on these two distinct assets.

  1. The "JNTX" Link: January Therapeutics and JNTX-101 The prefix "JNTX" is a direct and logical link to the developer January Therapeutics, Inc..42 While the specific designation "JNTX-102" is not found in the company's documented pipeline, the same source clearly lists JNTX-101 as a preclinical asset for solid tumors.[42] Further research confirms that JNTX-101 is a novel albumin-encapsulated gemcitabine prodrug that operates via Caveolin-1-mediated endocytosis.[3] Given the identical developer prefix and the shared therapeutic area (oncology), it is highly probable that "JNTX-102" is a misnomer for the company's lead preclinical program, JNTX-101.
  2. The "GNX" Typographical Hypothesis: GlycoNex Inc. and GNX-102 A common source of error in the transmission of pharmaceutical intelligence is minor typographical mistakes. The substitution of the letter 'G' for 'J' is a plausible error, which would transform "JNTX" into "GNX." This hypothesis points directly to GNX-102, the lead clinical-stage asset of GlycoNex Inc., a biotechnology company specializing in glycan-targeted cancer immunotherapies.8 This hypothesis is strongly supported by the substantial volume of data available for GNX-102, including details of its completed Phase 1 clinical trial (NCT04250597), its mechanism of action, and its strategic evolution into an antibody-drug conjugate.6 The clinical advancement and strategic relevance of GNX-102 make it a subject of high interest for industry analysis and a highly probable candidate for the query.

III. Deep Dive: January Therapeutics' Albumin-Bound Prodrug Platform (JNTX-101)

### Scientific Foundation: A Rational Approach to Enhancing Chemotherapy

The JNTX-101 program from January Therapeutics is founded on a scientifically rational strategy to improve the therapeutic properties of a well-established chemotherapeutic agent, gemcitabine. This approach focuses not on discovering a novel cytotoxic mechanism but on optimizing drug delivery to enhance efficacy and mitigate toxicity. The platform is built on two core principles: the prodrug concept coupled with albumin binding, and a targeted cellular uptake mechanism mediated by Caveolin-1.

#### The Prodrug Concept and Albumin Binding

Gemcitabine is an FDA-approved nucleoside analog used in the treatment of various solid tumors, including non-small cell lung cancer, pancreatic cancer, breast cancer, and bladder cancer.[4] However, its clinical utility is often limited by a short plasma half-life and significant systemic toxicities, such as myelosuppression. JNTX-101 addresses these limitations by being a prodrug of gemcitabine, specifically JTX-836, which is formulated into albumin-bound nanoparticles.[4]

This strategy is analogous to other successful prodrug platforms, such as the doxorubicin prodrug IPBA-Dox, which was shown to avidly bind human serum albumin (HSA) in circulation.[45] By binding to albumin, the most abundant protein in human plasma, the drug is expected to benefit from:

  1. Improved Pharmacokinetics: Albumin binding significantly extends the drug's circulatory half-life, preventing rapid clearance and allowing for prolonged exposure of the tumor to the therapeutic agent.
  2. Enhanced Tumor Accumulation: The nanoparticle formulation can exploit the Enhanced Permeability and Retention (EPR) effect, a phenomenon where macromolecules and nanoparticles preferentially accumulate in tumor tissue due to leaky vasculature and poor lymphatic drainage.
  3. Reduced Systemic Toxicity: By remaining largely inert while bound to albumin in circulation, the prodrug minimizes exposure of healthy tissues to the active cytotoxic agent, thereby widening the therapeutic window. The analogous doxorubicin prodrug was well-tolerated at concentrations where the parent drug was lethal, underscoring the potential safety benefits of this approach.[45]

#### Targeted Uptake via Caveolin-1 (Cav-1)

The most innovative aspect of the JNTX-101 platform is its reliance on a specific biological pathway for cellular entry: Caveolin-1 (Cav-1)-mediated endocytosis.[3] Cav-1 is a principal structural component of caveolae, which are small invaginations of the plasma membrane involved in signal transduction and endocytosis. Tumors, particularly those with high metabolic demands, are known to take up and metabolize albumin as a source of amino acids for growth.[4] The JNTX-101 platform hypothesizes that this uptake is mediated by Cav-1 and that the drug can effectively hijack this pathway.

Preclinical studies have provided direct evidence for this mechanism. In a panel of pancreatic and lung cancer cell lines, increased Cav-1 expression correlated with higher uptake of albumin and, consequently, greater sensitivity to JNTX-101.[4] Conversely, the depletion of Cav-1 in these cells attenuated their sensitivity to the drug.[4] This finding is of profound strategic importance, as it elevates Cav-1 from merely a component of the drug's mechanism to a potential predictive biomarker. A validated biomarker would enable a precision medicine strategy, allowing for the selection of patients most likely to respond to treatment, which can lead to more efficient clinical trials and a clearly defined market upon approval.[5]

### Preclinical Evidence and Therapeutic Profile

#### Manufacturing and Formulation

JNTX-101 is manufactured as a lyophilized powder for reconstitution. The process involves the high-shear emulsification of an aqueous solution of albumin with an organic solution containing the gemcitabine prodrug, JTX-836 (MW: 697.76 g/mol).[4] After the emulsion is formed, the organic solvent is removed, and the resulting solution is sterile-filtered and lyophilized. This process yields a drug product with a consistent nanoparticle profile. Nanoparticle tracking analysis determined a typical median particle hydrodynamic diameter of 64 nm, with 90% of particles having a diameter of less than 92 nm. Upon reconstitution, the particle concentration is approximately

2×1012 particles/mL.[4] These specific manufacturing details indicate a well-characterized and controlled drug product, which is a critical prerequisite for advancing into clinical development and ensuring regulatory compliance.

#### In Vitro and In Vivo Efficacy

Preclinical data have demonstrated that JNTX-101 effectively inhibits cell viability in cancer cell lines and suppresses tumor growth in vivo.[4] The core of its efficacy is directly linked to the Cav-1 expression level, as previously described. While the available materials confirm these positive findings, they lack specific quantitative data, such as

IC50​ values for cell viability or percentage of tumor growth inhibition in xenograft models. This absence of detailed preclinical efficacy metrics represents a significant data gap for a comprehensive evaluation of the drug's potency relative to standard gemcitabine or other investigational agents.

### Strategic and Competitive Positioning

#### Development Stage

JNTX-101 is currently in the Preclinical phase of development for the treatment of solid tumors.[42] This early stage carries a high degree of development risk and implies a multi-year timeline before potential regulatory approval. The immediate next steps would involve completing IND-enabling toxicology studies and filing an IND application with the FDA to initiate Phase 1 clinical trials.

#### Competitive Landscape

The strategy of enhancing chemotherapy through albumin binding is not new. The most prominent success in this area is Abraxane (nab-paclitaxel), an albumin-bound nanoparticle formulation of paclitaxel approved for breast cancer, non-small cell lung cancer, and pancreatic cancer.[46] JNTX-101 will inevitably be compared to this established therapeutic. The key distinction, and JNTX-101's primary competitive advantage, is its proposed biomarker-driven approach. While Abraxane's uptake is thought to be mediated in part by the SPARC protein, its use is not restricted to a biomarker-selected population. JNTX-101's reliance on Cav-1 offers the potential for superior efficacy in a well-defined patient subset.

The success of the JNTX-101 program will therefore depend critically on the clinical validation of Cav-1 as a robust and reliable predictive biomarker. This is the central value proposition that differentiates it from existing therapies and other albumin-based technologies in development.

Drug Name (Brand)PayloadApproved IndicationsNovel Mechanism/TargetingDeveloperDevelopment Stage
JNTX-101Gemcitabine (Prodrug)NoneCaveolin-1 (Cav-1) mediated uptakeJanuary TherapeuticsPreclinical 42
AbraxanePaclitaxelMetastatic Breast Cancer, NSCLC, Pancreatic CancerAlbumin-mediated transport (gp60/SPARC)Celgene/BMSMarketed 46
IPBA-DoxDoxorubicin (Prodrug)NoneAlbumin binding, Cav-1 selectivityAcademic ResearchPreclinical 45

IV. Deep Dive: GlycoNex Inc.'s Glycan-Targeting Program (GNX-102 and GNX-102-ADC)

### Scientific Foundation: Targeting Aberrant Glycosylation, a Hallmark of Cancer

The GNX-102 program is built upon a sophisticated biological principle: targeting the aberrant glycosylation patterns that are a universal feature of cancer cells. This approach moves beyond traditional protein targets to exploit a different class of molecules—glycans—that are highly specific to the malignant phenotype.

#### Introduction to Glycobiology in Oncology

Glycosylation, the enzymatic process of attaching sugar chains (glycans) to proteins and lipids, is profoundly altered during tumorigenesis.[48] These alterations result in the expression of unique glycan structures on the cancer cell surface known as tumor-associated carbohydrate antigens (TACAs).[6] Because these TACAs are rarely expressed on normal, healthy tissues, they represent an ideal class of targets for cancer therapy, offering the potential for high tumor specificity and a wide therapeutic window.[51] The field of glyco-oncology seeks to develop therapies, including monoclonal antibodies, ADCs, and vaccines, that can recognize and target these TACAs.[48]

#### The Target: Lewis-Y Antigen

GNX-102 is a humanized IgG1 monoclonal antibody specifically designed to target novel TACAs.[6] More specifically, its target has been identified as the

Lewis-Y antigen (also known as CD174), a difucosylated oligosaccharide.[7] Immunohistochemistry (IHC) profiling has shown that the target of GNX-102 is expressed on a wide spectrum of high-incidence epithelial cancers, including colorectal, gastric, non-small cell lung, bladder, pancreatic, breast, esophageal, and prostate cancers.[6] This broad expression profile makes the Lewis-Y antigen a highly attractive target for a "pipeline-in-a-product" strategy, with potential applicability across numerous solid tumor indications.

#### Mechanism of Action (Naked Antibody)

In its original form as a "naked" humanized IgG1 antibody, GNX-102 is designed to exert its anti-tumor effects primarily through the engagement of the host immune system.[6] The IgG1 Fc region is potent at mediating effector functions. Upon binding to the Lewis-Y antigen on the cancer cell surface, the Fc portion of GNX-102 acts as a flag for immune cells. This can trigger:

  • Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC): Natural Killer (NK) cells recognize the Fc region and release cytotoxic granules (perforin and granzymes) to kill the targeted cancer cell.
  • Complement-Dependent Cytotoxicity (CDC): The antibody can activate the complement cascade, leading to the formation of a membrane attack complex that lyses the cancer cell.

Preclinical xenograft models of stomach and colorectal cancer demonstrated that GNX-102 could achieve "remarkable tumor suppression," primarily through these Fc-mediated mechanisms.[6]

### Clinical Development: The Phase 1 Trial of GNX-102 (NCT04250597)

GlycoNex advanced GNX-102 into a first-in-human clinical trial to assess its safety, tolerability, and pharmacokinetics, and to determine the MTD.

#### Trial Design and Execution

The study, designated GNX-001 (NCT04250597), was a Phase 1, open-label, multi-center, dose-escalation and expansion study.[9] A total of 46 adult patients with advanced, unresectable, or metastatic solid tumors were enrolled.[9] Eligible tumor types included a wide range of epithelial-origin cancers with a likelihood of expressing the target antigen, such as colorectal, gastric, NSCLC, pancreatic, and breast cancer.[9] The trial employed a sequential assignment model for dose escalation, with GNX-102 administered as an intravenous infusion every 21 days.[9] The primary objective was to determine the MTD, defined by the rate of dose-limiting toxicities (DLTs).[9]

#### Timeline

The trial was first posted on ClinicalTrials.gov on January 31, 2020, with an actual study start date of July 29, 2020.[9] The trial was initially conducted in the United States and later expanded to include sites in Taiwan in February 2023 to accelerate the process.[56] The study's primary and overall completion date is listed as July 26, 2023.[9]

#### Reported Results (Qualitative)

Across numerous company communications, GlycoNex has consistently characterized the outcome of the Phase 1 trial in positive, albeit qualitative, terms. The study was "successfully completed," and GNX-102 demonstrated an "excellent safety profile," "strong safety and tolerability," and "promising efficacy".[8] The company also confirmed that the MTD was successfully determined.[6]

However, a critical observation is the absence of any public disclosure of quantitative efficacy data from this trial. Searches for presentations at major oncology conferences such as the American Society of Clinical Oncology (ASCO), the European Society for Medical Oncology (ESMO), or the American Association for Cancer Research (AACR) did not yield any results detailing objective response rates (ORR), duration of response (DoR), or progression-free survival (PFS) for the GNX-102 monotherapy.[37] This pattern—touting safety and "promising" efficacy in press releases while withholding concrete response data from scientific forums—is highly significant. It strongly suggests that while the antibody proved to be safe and capable of engaging its target, its standalone clinical activity as a monotherapy was likely modest, consisting primarily of stable disease rather than significant tumor regressions. This realization would have been the primary driver for the company's subsequent strategic pivot.

### Strategic Evolution to an Antibody-Drug Conjugate (GNX-102-ADC)

#### Rationale for the Pivot

The decision to reformat GNX-102 as an ADC represents a logical and strategically sound evolution of the program. Initiated "soon after" the completion of the Phase 1 study, this pivot leverages the most valuable asset demonstrated in the trial—the antibody's excellent safety profile and its validated ability to target tumor cells—and combines it with a mechanism to dramatically increase potency.[6] An ADC functions as a "biological missile," using the antibody to deliver a highly toxic payload directly to cancer cells, thereby killing them with high specificity while minimizing systemic exposure and associated side effects.[10] For an antibody with a novel, tumor-specific target but modest intrinsic activity, conversion to an ADC is the optimal path to creating a highly effective therapeutic.

#### The ADC Construct and Development Plan

The GNX-102-ADC combines the proprietary GNX-102 mAb with an unspecified "cytotoxic drug" payload.[10] While the exact payload has not been disclosed, the most common classes used in modern ADCs are microtubule inhibitors (e.g., MMAE, MMAF), maytansinoids (e.g., DM1, DM4), and topoisomerase I inhibitors (e.g., SN-38, deruxtecan), all of which are highly potent agents unsuitable for systemic administration on their own.[72]

GlycoNex has taken concrete steps to advance this program. In November 2024, the company announced a crucial manufacturing agreement with Sterling Pharma Solutions, a contract development and manufacturing organization (CDMO) with specialized expertise in ADC production, for the manufacturing of clinical trial material.[11] This partnership is a clear indicator that the program is moving toward the clinic. The company has stated its intention to initiate a

Phase 1 clinical program for GNX-102-ADC.[11] Preclinical studies of the ADC have already yielded positive results, demonstrating "strong tumor-suppressing potential" in animal models of gastric, colorectal, pancreatic, and lung cancer, with a safety profile described as "comparable to approved ADCs".[11]

#### Broader Platform Strategy

GlycoNex's ambitions in glyco-oncology extend beyond a single asset. This is evidenced by a multi-pronged pipeline strategy that mitigates risk and leverages its core expertise:

  • GNX-1021: This is a second, distinct ADC program that targets branched Lewis B/Y (bLeB/Y), a glycan antigen overexpressed in gastric cancer and other solid tumors.[43] Preclinical data for GNX-1021 was presented at AACR in 2025, and the company plans an IND submission in Q1 2026, with a Phase 1 trial initiation in Q2 2026.[68]
  • GNX201 (Pro-Antibody Platform): In collaboration with PrecisemAb Biotech, GlycoNex is developing a "pro-antibody" technology.[7] This involves fusing a "masking" peptide to the antibody's binding region via a linker that is cleavable by proteases found specifically in the tumor microenvironment (TME).[6] This design keeps the antibody "off" in normal circulation to prevent on-target, off-tumor toxicity, and "turns it on" only at the tumor site, potentially creating a much safer generation of anti-glycan therapies.[59]

This portfolio approach—advancing a lead ADC, exploring a second ADC against a new target, and developing next-generation safety technology—demonstrates a sophisticated and comprehensive strategy to establish a leadership position in the emerging field of glyco-oncology.

### Intellectual Property and Global Strategy

A strong intellectual property portfolio is essential for commercial success. GlycoNex has been diligent in securing global rights for its lead asset. The company has been granted a composition of matter patent for GNX-102 by the United States Patent and Trademark Office (USPTO) under U.S. Patent No. 1440967.[10] This foundational patent has been supplemented by the issuance of corresponding patents in other key global markets, including Japan, South Korea, Russia, and Taiwan.[10] This robust patent estate provides a strong basis for market exclusivity and enhances the program's value for potential partnerships or licensing agreements.

V. Synthesis, Outlook, and Strategic Recommendations

### Head-to-Head Comparison: JNTX-101 vs. GNX-102 Program

A direct comparison of the two programs reveals distinct profiles in terms of technology, development stage, risk, and market potential.

FeatureJanuary Therapeutics' JNTX-101GlycoNex Inc.'s GNX-102 Program
TechnologyNovel drug delivery platform for an established chemotherapy (gemcitabine). Innovation is in the albumin-binding and Cav-1 targeting.Novel biological target (Lewis-Y TACA) combined with a validated therapeutic modality (antibody-drug conjugate).
Development StagePreclinical. Awaiting IND-enabling studies and first-in-human trial.Clinical. Naked mAb Phase 1 complete. ADC is now in preclinical/manufacturing phase, preparing for its own Phase 1 trial.
Risk ProfileLower biological risk (payload efficacy is known). Higher platform risk (clinical validation of Cav-1 as a predictive biomarker is critical and unproven).Higher biological risk (Lewis-Y is a novel target class for ADCs). Lower modality risk (ADCs are a clinically and commercially validated platform).
Market PotentialTargeted, biomarker-defined (Cav-1 high) patient populations within major solid tumors (e.g., pancreatic, lung).Potentially broad applicability across numerous solid tumors expressing the Lewis-Y antigen. The ADC format aims for high efficacy, potentially in later lines of therapy.

### Competitive Landscape and Future Trajectory

#### JNTX-101 Platform

The JNTX-101 platform is positioned within the competitive space of "chemotherapy enhancement." Its primary competitor is the established blockbuster Abraxane (nab-paclitaxel), which validated the commercial potential of albumin-based drug delivery.[46] To succeed, JNTX-101 must demonstrate not just non-inferiority but clear clinical superiority over standard gemcitabine and potentially a better safety profile or efficacy in a specific, identifiable patient population (i.e., Cav-1 high tumors) compared to other options.

#### GNX-102 Program

The GNX-102 program competes on two fronts: the niche but growing field of TACA-targeting therapies and the large, dynamic ADC market.

1. TACA-Targeting Therapies: Targeting glycans is an emerging field. While the concept has been explored for decades, clinical success has been limited, with the notable exception of anti-GD2 antibodies (e.g., Dinutuximab) for neuroblastoma.[49] Previous attempts to target the Lewis-Y antigen with naked monoclonal antibodies showed insufficient efficacy, leading to trial terminations.[78] This historical context underscores the challenge of targeting TACAs and strongly supports GlycoNex's strategic pivot to the much more potent ADC modality. The competitive landscape includes other companies developing therapies against TACAs like Globo H, but the Lewis-Y ADC space appears less crowded.

Drug/Program NameTarget AntigenModalityDeveloperHighest Development StageKey Differentiators/Notes
GNX-102-ADCLewis-YADCGlycoNex Inc.Preclinical (ADC)Leverages a Phase 1-validated mAb for targeting.
m3s193 BsAbLewis-Y, CD3Bispecific AbAcademic ResearchPreclinicalT-cell engaging bispecific antibody format.53
hu3S193Lewis-YmAbAcademic/LegacyPhase 1/2 (Terminated)Early mAb effort with limited efficacy.78
OBI-999Globo HADCOBI PharmaPhase 2Targeting a different glycan (Globo H) with an ADC format.79
OBI-888Globo HmAbOBI PharmaPhase 1/2Naked mAb targeting Globo H.79
DinutuximabGD2mAbUnited TherapeuticsMarketedApproved benchmark for TACA-targeting in neuroblastoma.49

2. Antibody-Drug Conjugates: The ADC market is a multi-billion-dollar sector with numerous approved products like Enhertu, Trodelvy, and Padcev, and hundreds more in development.[52] GNX-102-ADC's novelty within this crowded space is not its payload or linker technology but its unique target class. By targeting a TACA, it has the potential to treat tumors that do not express the conventional protein targets (like HER2 or Trop-2) of existing ADCs, thereby addressing a significant unmet need.

### Expert Insights and Recommendations

The analysis of these two distinct programs, unearthed from the ambiguous "JNTX-102" query, leads to several key conclusions and actionable recommendations for stakeholders in the biopharmaceutical and investment communities.

#### Key Inflection Points to Monitor

  • For January Therapeutics (JNTX-101):
  • Near-Term: Successful filing of an IND with the FDA. This will be the first major validation of its preclinical data package and manufacturing processes.
  • Mid-Term: Initial data from the Phase 1 trial. The primary focus will be on safety, tolerability, and pharmacokinetics, confirming that the albumin-bound prodrug behaves as expected in humans.
  • Long-Term (Critical): Data from Phase 1 expansion cohorts or a Phase 2 trial that establishes a clear correlation between Cav-1 expression levels and clinical response (e.g., tumor shrinkage, duration of stable disease). This biomarker validation is the single most critical value driver for the entire platform.
  • For GlycoNex Inc. (GNX-102 Program):
  • Near-Term: Public disclosure of quantitative efficacy data from the completed Phase 1 trial of the naked GNX-102 antibody. While unlikely to show high response rates, this data is essential for validating the antibody's target engagement and providing a baseline for the ADC.
  • Mid-Term: Successful IND filing for the GNX-102-ADC. This will signal the program's official transition to a clinical-stage ADC asset.
  • Long-Term (Critical): Initial safety and efficacy data from the first-in-human trial of GNX-102-ADC. Early signs of objective responses (partial or complete responses) in this trial would be a major de-risking event and a significant value inflection point, validating Lewis-Y as a viable ADC target.

#### Critical Data Gaps

  • GNX-102: The most significant data gap is the complete absence of published quantitative efficacy data (ORR, DoR, PFS) from the 46-patient Phase 1 trial of the naked antibody.
  • GNX-102-ADC: The chemical identity of the cytotoxic payload and the specifics of the linker technology are currently undisclosed. These are critical determinants of an ADC's efficacy and toxicity profile.
  • JNTX-101: All available data is preclinical. The translation of its efficacy and the Cav-1 biomarker hypothesis from animal models to human patients is the program's largest unknown.

#### Actionable Recommendations

  1. For Strategic Evaluation/Partnership: GlycoNex's GNX-102 program warrants priority for deep diligence due to its more advanced clinical stage, robust intellectual property, and strategic positioning in the high-growth ADC market. However, any engagement must press for clarification on the Phase 1 monotherapy efficacy data and the identity of the ADC payload. The decision to pivot to an ADC was strategically astute, but it implicitly suggests the monotherapy's efficacy was modest. The success of the program now rests entirely on the ADC. January Therapeutics' JNTX-101 represents a higher-risk, earlier-stage opportunity, but one with a potentially cleaner path through development if the Cav-1 biomarker is validated. It is an attractive asset for partners with expertise in companion diagnostics.
  2. For Competitive Intelligence: Actively monitor major oncology conferences (ASCO, ESMO, AACR) and GlycoNex's corporate disclosures for any release of the GNX-102 Phase 1 data or details on the GNX-102-ADC construct. The initiation of the GNX-102-ADC Phase 1 trial will be a key event to track. For January Therapeutics, the primary deliverable to watch for is an IND filing announcement or a preclinical data presentation that includes quantitative in vivo efficacy results.
  3. For Investment Thesis:
  • An investment in GlycoNex is a "platform" investment in the emerging and scientifically compelling field of glyco-oncology. The thesis is that TACAs represent a new frontier of cancer-specific targets, and ADCs are the optimal modality to exploit them. The company's multi-asset pipeline (GNX-102-ADC, GNX-1021, GNX201) diversifies this risk. The primary risk is the clinical validation of this novel target class, which has a history of challenges.
  • An investment in January Therapeutics is a more focused, "bio-better" thesis. It is a bet on improving an existing standard of care (gemcitabine) through a novel delivery and targeting system. The biological risk of the payload is negligible; the entire investment thesis hinges on the successful clinical validation of the Cav-1 biomarker strategy to unlock superior efficacy in a defined patient population.

Works cited

  1. JNTX-102 | MedPath, accessed August 25, 2025, https://trial.medpath.com/drug/f378991e41a52746/jntx-102
  2. Request a quote for JN15G20,JN171158,JN171499. - ISO Group, accessed August 25, 2025, https://www.iso-group.com/Inventory/4508
  3. ‪Nicholas Raheja‬ - ‪Google Scholar‬, accessed August 25, 2025, https://scholar.google.com/citations?user=-HLmbJ0AAAAJ&hl=en
  4. JNTX-101, a novel albumin-encapsulated gemcitabine prodrug, is efficacious and operates via caveolin-1-mediated endocytosis - PubMed Central, accessed August 25, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10477748/
  5. City of Hope's Abstract Presentations at the AACR Annual Meeting 2022, accessed August 25, 2025, https://www.cityofhope.org/sites/www/files/2022-06/aacr-2022-program-guide-final.pdf
  6. GlycoNex INC., accessed August 25, 2025, https://www.glyconex.com.tw/index.php/en-us/product-pipeline-us
  7. GNX-102 - Drug Targets, Indications, Patents - Patsnap Synapse, accessed August 25, 2025, https://synapse-patsnap-com.libproxy1.nus.edu.sg/drug/2a58d1ea62f34cf2bf4435dc377b6814
  8. GlycoNex & PrecisemAb Sign Technology Licensing Agreement to Advance Development of Novel Anti-Glycan Antibodies for Cancer Therapy, accessed August 25, 2025, https://drug-dev.com/glyconex-precisemab-sign-technology-licensing-agreement-to-advance-development-of-novel-anti-glycan-antibodies-for-cancer-therapy/
  9. Study of GNX102 in Patients With Advanced Solid Tumors - ClinicalTrials.gov, accessed August 25, 2025, https://clinicaltrials.gov/study/NCT04250597
  10. GlycoNex Enhances Global Intellectual Property Estate for GNX102 with Patent Approvals in Japan, South Korea, Russia and Taiwan - PR Newswire, accessed August 25, 2025, https://www.prnewswire.com/news-releases/glyconex-enhances-global-intellectual-property-estate-for-gnx102-with-patent-approvals-in-japan-south-korea-russia-and-taiwan-302179379.html
  11. GlycoNex Announces Manufacturing Agreement with Sterling for GNX102-ADC Clinical Trial Production - PR Newswire, accessed August 25, 2025, https://www.prnewswire.com/news-releases/glyconex-announces-manufacturing-agreement-with-sterling-for-gnx102-adc-clinical-trial-production-302301504.html
  12. TAS-102: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed August 25, 2025, https://go.drugbank.com/drugs/DB08937
  13. Trifluridine/tipiracil - Wikipedia, accessed August 25, 2025, https://en.wikipedia.org/wiki/Trifluridine/tipiracil
  14. TAS-102 Improves Overall Survival in Patients with Metastatic Colorectal Cancer, accessed August 25, 2025, https://www.cancer.gov/types/colorectal/research/tas-102-overall-survival
  15. Clinical Evaluation of the Safety and Efficacy of Trifluridine/Tipiracil in the Treatment of Advanced Gastric/Gastroesophageal Junction Adenocarcinoma: Evidence to Date - PubMed Central, accessed August 25, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7398745/
  16. Tipiracil: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed August 25, 2025, https://go.drugbank.com/drugs/DB09343
  17. GTX-102 for Angelman Syndrome (AS) - Ultragenyx Pharmaceutical, accessed August 25, 2025, https://www.ultragenyx.com/our-research/pipeline/gtx-102-for-angelman-syndrome/
  18. GTX-102: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed August 25, 2025, https://go.drugbank.com/drugs/DB16981
  19. GeneTx and Ultragenyx Announce First Patient Dosed in Phase 1/2 Clinical Trial of GTX-102 in Patients with Angelman Syndrome, accessed August 25, 2025, https://ir.ultragenyx.com/news-releases/news-release-details/genetx-and-ultragenyx-announce-first-patient-dosed-phase-12
  20. Ultragenyx Presents Positive Update on GTX-102 Angelman Syndrome Program at FAST's 17th Annual Global Science Summit, accessed August 25, 2025, https://ir.ultragenyx.com/news-releases/news-release-details/ultragenyx-presents-positive-update-gtx-102-angelman-syndrome
  21. Angelman Syndrome Therapies Show Positive Results in Early Phase Clinical Trials, accessed August 25, 2025, https://www.oligotherapeutics.org/angelman-syndrome-therapies-show-positive-results-in-early-phase-clinical-trials/
  22. Study Details | Long-term Extension of GTX-102 in Angelman Syndrome - ClinicalTrials.gov, accessed August 25, 2025, https://clinicaltrials.gov/study/NCT06415344
  23. A Study of the Safety and Tolerability of GTX-102 in Children with Angelman Syndrome, accessed August 25, 2025, https://clinicaltrials.gov/study/NCT04259281
  24. Ultragenyx Receives Breakthrough Therapy Designation for GTX-102 in Angelman Syndrome, accessed August 25, 2025, https://ir.ultragenyx.com/news-releases/news-release-details/ultragenyx-receives-breakthrough-therapy-designation-gtx-102
  25. A Phase 3 Study to Evaluate the Efficacy and Safety of TNX-102 SL Taken Daily in Patients With Fibromyalgia | ClinicalTrials.gov, accessed August 25, 2025, https://www.clinicaltrials.gov/study/NCT05273749
  26. Tonix Pharmaceuticals Announces On-line Publication of Phase 3 RESILIENT Trial Results of TNX-102 SL for Fibromyalgia in the Peer Reviewed Journal, Pain Medicine - GlobeNewswire, accessed August 25, 2025, https://www.globenewswire.com/news-release/2025/07/09/3112862/0/en/Tonix-Pharmaceuticals-Announces-On-line-Publication-of-Phase-3-RESILIENT-Trial-Results-of-TNX-102-SL-for-Fibromyalgia-in-the-Peer-Reviewed-Journal-Pain-Medicine.html
  27. Tonix TNX-102 SL: Innovating Fibromyalgia Treatment in Development, accessed August 25, 2025, https://www.clinicaltrialvanguard.com/executiveinterviews/tonix-tnx-102-sl-innovating-fibromyalgia-treatment-in-development/
  28. Tonix Pharmaceuticals Announces FDA PDUFA Goal Date for TNX-102 SL and Positive Developments Across Pipeline | Nasdaq, accessed August 25, 2025, https://www.nasdaq.com/articles/tonix-pharmaceuticals-announces-fda-pdufa-goal-date-tnx-102-sl-and-positive-developments
  29. Tonix Pharmaceuticals Announces Publication of Results from Phase 3 RELIEF Trial of TNX-102 SL for the Management of Fibromyalgia, accessed August 25, 2025, https://ir.tonixpharma.com/news-events/press-releases/detail/1400/tonix-pharmaceuticals-announces-publication-of-results-from
  30. Tonix Pharmaceuticals Completes Clinical Stage of Phase 3 RESILIENT Study of TNX-102 SL for the Management of Fibromyalgia, accessed August 25, 2025, https://ir.tonixpharma.com/news-events/press-releases/detail/1439/tonix-pharmaceuticals-completes-clinical-stage-of-phase-3
  31. ONCOS- 102 Mesothelioma Immunotherapy Medication, accessed August 25, 2025, https://mesotheliomahub.com/treatment/immunotherapy/medications/oncos-102/
  32. ONCOS-102 for Malignant Mesothelioma, accessed August 25, 2025, https://www.mesotheliomaguide.com/treatment/cure/virotherapy/oncos-102-for-mesothelioma/
  33. Pilot Study of ONCOS-102 and Pembrolizumab: Remodeling of the Tumor Microenvironment and Clinical Outcomes in Anti-PD-1-Resistant Advanced Melanoma - PubMed, accessed August 25, 2025, https://pubmed.ncbi.nlm.nih.gov/36112545/
  34. Phase I study with ONCOS-102 for the treatment of solid tumors - an evaluation of clinical response and exploratory analyses of immune markers - PubMed, accessed August 25, 2025, https://pubmed.ncbi.nlm.nih.gov/26981247/
  35. Etirinotecan pegol (NKTR-102) versus treatment of physician's choice in women with advanced breast cancer previously treated with an anthracycline, a taxane, and capecitabine (BEACON): a randomised, open-label, multicentre, phase 3 trial - PubMed, accessed August 25, 2025, https://pubmed.ncbi.nlm.nih.gov/26482278/
  36. The BEACON Study (Breast Cancer Outcomes With NKTR-102) - ClinicalTrials.gov, accessed August 25, 2025, https://clinicaltrials.gov/study/NCT01492101
  37. A first-in-human, phase 1/2a study of GI-102 (CD80-IL2v3) in patients with advanced or metastatic solid tumors: Initial results from dose escalation. - ASCO, accessed August 25, 2025, https://www.asco.org/abstracts-presentations/ABSTRACT460384
  38. A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08) - NCI, accessed August 25, 2025, https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2023-10653
  39. A Phase 1a/2 Study of GI-102 Immunotherapy in People With Advanced Sarcoma | Memorial Sloan Kettering Cancer Center, accessed August 25, 2025, https://www.mskcc.org/cancer-care/clinical-trials/24-094
  40. Study of SC-102 in Patients With Advanced Solid Tumors - ClinicalTrials.gov, accessed August 25, 2025, https://clinicaltrials.gov/study/NCT06710158
  41. An Open-Label, Multicenter, First-in-Human Clinical Trial of PTX-102 mRNA Vaccine in Patients with Advanced Solid Tumors - BioCanRx, accessed August 25, 2025, https://biocanrx.com/wp-content/uploads/2025/06/Dashboard-Oza-PTX-102-mRNA-Vaccine-Trial.pdf
  42. January Therapeutics, Inc. - Drug pipelines, Patents, Clinical trials - Patsnap Synapse, accessed August 25, 2025, https://synapse.patsnap.com/organization/931f85773c7de1123424433d99314b5a
  43. GlycoNex to Participate in BIO Asia-Taiwan 2025 - PR Newswire, accessed August 25, 2025, https://www.prnewswire.com/news-releases/glyconex-to-participate-in-bio-asia-taiwan-2025-302508904.html
  44. GlycoNex Partners with Sterling for GNX102-ADC Clinical Trial Manufacturing, accessed August 25, 2025, https://pharmasource.global/content/news/cdmo-news/glyconex-partners-with-sterling-for-gnx102-adc-clinical-trial-manufacturing/
  45. Improved Targeting and Safety of Doxorubicin through a Novel Albumin Binding Prodrug Approach | ACS Omega, accessed August 25, 2025, https://pubs.acs.org/doi/10.1021/acsomega.3c07163
  46. Study Details | Albumin-bound Paclitaxel (ABI-007) for Patients With Advanced Non-Small Cell Lung Cancer | ClinicalTrials.gov, accessed August 25, 2025, https://clinicaltrials.gov/study/NCT00540514
  47. Albumin-Bound Paclitaxel: Worthy of Further Study in Sarcomas - Frontiers, accessed August 25, 2025, https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2022.815900/full
  48. Tumor-Associated Glycans as Targets for Immunotherapy: The Wistar Institute Experience/Legacy - PMC - PubMed Central, accessed August 25, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8336226/
  49. Targeting Tumor Glycans for Cancer Therapy: Successes, Limitations, and Perspectives - PMC - PubMed Central, accessed August 25, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8833780/
  50. Targeting Tumor Glycans for Cancer Therapy - Glycopedia, accessed August 25, 2025, https://glycopedia.eu/2024/02/21/targeting-tumor-glycans-for-cancer-therapy/
  51. Full article: Targeting cancer-associated glycans as a therapeutic strategy in leukemia, accessed August 25, 2025, https://www.tandfonline.com/doi/full/10.1080/26895293.2022.2049901
  52. Glycans as Targets for Drug Delivery in Cancer - MDPI, accessed August 25, 2025, https://www.mdpi.com/2072-6694/14/4/911
  53. A Novel Bispecific Antibody Targeting CD3 and Lewis Y with Potent Therapeutic Efficacy against Gastric Cancer - MDPI, accessed August 25, 2025, https://www.mdpi.com/2227-9059/9/8/1059
  54. What are Lewis-Y antigen modulators and how do they work? - Patsnap Synapse, accessed August 25, 2025, https://synapse.patsnap.com/article/what-are-lewis-y-antigen-modulators-and-how-do-they-work
  55. Clinical Trial: NCT04250597 - My Cancer Genome, accessed August 25, 2025, https://www.mycancergenome.org/content/clinical_trials/NCT04250597/
  56. GlycoNex Inc. kicks off its trial for cancer drug GNX-102 in Taiwan | Healthcare+ B2B, accessed August 25, 2025, https://www.taiwan-healthcare.org/en/lang?_=news-detail%3Fid%3D0rq953kgeo2hdrl0
  57. In the news - Society of Utah Medical Oncologists, accessed August 25, 2025, https://sumocancer.org/In_the_news?rkey=20250428NY73399&filter=14438
  58. GlycoNex Announces First Patient Dosed in Phase 3 Clinical Trial for Denosumab Biosimilar, accessed August 25, 2025, https://www.prnewswire.com/news-releases/glyconex-announces-first-patient-dosed-in-phase-3-clinical-trial-for-denosumab-biosimilar-302333701.html
  59. GlycoNex Announces Publication of Research Involving Pro-Antibody, GNX201, in the International Journal of Biological Macromolecules - FirstWord Pharma, accessed August 25, 2025, https://firstwordpharma.com/story/5966705
  60. GlycoNex Enhances Global Intellectual Property Estate for GNX102 with Patent Approvals in Japan, South Korea, Russia and Taiwan - FirstWord Pharma, accessed August 25, 2025, https://firstwordpharma.com/story/5869524
  61. Selpercatinib in RET Fusion–Positive Non–Small Cell Lung Cancer: Final Safety and Efficacy, Including Overall Survival, From the LIBRETTO-001 Phase I/II Trial - ASCO Publications, accessed August 25, 2025, https://ascopubs.org/doi/10.1200/JCO-24-02076
  62. A first-in-human, phase 1/2a study of GI-102 (CD80-IL2v3) in patients with advanced or metastatic solid tumors: Initial results from dose escalation. - ASCO, accessed August 25, 2025, https://www.asco.org/posters/POSTER233987
  63. A phase Ib/IIa study of NEO-102: A therapeutic antibody to treat pancreatic and colorectal cancers. - ASCO, accessed August 25, 2025, https://www.asco.org/abstracts-presentations/ABSTRACT122613
  64. AMGEN TO PRESENT DATA FROM MULTIPLE EARLY-STAGE CLINICAL TRIALS AT ESMO 2024, accessed August 25, 2025, https://www.amgen.com/newsroom/press-releases/2024/09/amgen-to-present-data-from-multiple-early-stage-clinical-trials-at-esmo-2024
  65. MSK Researchers Report Exciting Cancer Research Advances at ESMO Congress 2024, accessed August 25, 2025, https://www.mskcc.org/clinical-updates/msk-researchers-report-exciting-cancer-research-advances-at-esmo-congress-2024
  66. ESMO 2024 - BioNTech, accessed August 25, 2025, https://investors.biontech.de/system/files-encrypted/nasdaq_kms/assets/2024/09/17/10-19-17/ESMO%202024_BNTX%20vFINAL.pdf
  67. GlycoNex to Present Novel Glycan-Targeting ADC Data for Gastric Cancer at AACR 2025, accessed August 25, 2025, https://trial.medpath.com/news/7f8701d88f77a29e/glyconex-to-present-novel-glycan-targeting-adc-data-for-gastric-cancer-at-aacr-2025
  68. GlycoNex to Present Preclinical Data on GNX1021 at AACR 2025 - PR Newswire, accessed August 25, 2025, https://www.prnewswire.com/news-releases/glyconex-to-present-preclinical-data-on-gnx1021-at-aacr-2025-302412175.html
  69. GlycoNex Presents Preclinical Data on GNX1021 at AACR Annual Meeting 2025, accessed August 25, 2025, https://www.prnewswire.com/news-releases/glyconex-presents-preclinical-data-on-gnx1021-at-aacr-annual-meeting-2025-302438903.html
  70. Promising study results reported in first clinical trials plenary - AACR Annual Meeting News, accessed August 25, 2025, https://www.aacrmeetingnews.org/news/promising-study-results-reported-in-first-clinical-trials-plenary/
  71. Syncromune® Inc. Presents Positive Results from SYNC-T SV-102 Phase 1 Trial at AACR Annual Meeting 2024, accessed August 25, 2025, https://syncromune.com/2024/04/08/syncromune-inc-presents-positive-results-from-sync-t-sv-102-phase-1-trial-at-aacr-annual-meeting-2024/
  72. What Are ADC Payloads? - Biopharma PEG, accessed August 25, 2025, https://www.biochempeg.com/article/394.html
  73. Antibody–drug conjugates: Recent advances in payloads - PMC - PubMed Central, accessed August 25, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10547921/
  74. GlycoNex Announces Manufacturing Agreement with Sterling for GNX102-ADC Clinical Trial Production, accessed August 25, 2025, https://www.sterlingpharmasolutions.com/knowledge-hub/news/glyconex-announces-manufacturing-agreement-with-sterling/
  75. 2025-04-28 GlycoNex AACR 2025 Poster Presentation GNX1021, accessed August 25, 2025, https://www.glyconex.com.tw/index.php/en-us/component/content/article/35-uncategorised-2/press-releases-2/2025-2/75-20250428
  76. GlycoNex Inc. 2024 Investor Conference, accessed August 25, 2025, https://www.glyconex.com.tw/images/media/2020/05_Investor_Conference/01_Report_Files/113.11.04%E5%8F%B0%E7%81%A3%E9%86%A3%E8%81%AF%E6%B3%95%E4%BA%BA%E8%AA%AA%E6%98%8E%E6%9C%83%E7%B0%A1%E5%A0%B1(%E8%8B%B1%E6%96%87).pdf
  77. GlycoNex Announces Publication of Research Involving Pro-Antibody, GNX201, in the International Journal of Biological Macromolecules - PR Newswire, accessed August 25, 2025, https://www.prnewswire.com/news-releases/glyconex-announces-publication-of-research-involving-pro-antibody-gnx201-in-the-international-journal-of-biological-macromolecules-302465373.html
  78. Lewis Y antigen expression of the patient with stable disease for more... - ResearchGate, accessed August 25, 2025, https://www.researchgate.net/figure/Lewis-Y-antigen-expression-of-the-patient-with-stable-disease-for-more-than-2-years-who_fig2_355239706
  79. Globo H - Wikipedia, accessed August 25, 2025, https://en.wikipedia.org/wiki/Globo_H
  80. Trends in the Development of Antibody-Drug Conjugates for Cancer Therapy - PMC, accessed August 25, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10660735/
  81. Evaluation of Two Chemoenzymatic Glycan Remodeling Approaches to Generate Site-Specific Antibody–Drug Conjugates - MDPI, accessed August 25, 2025, https://www.mdpi.com/2073-4468/12/4/71

Published at: August 25, 2025

This report is continuously updated as new research emerges.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.